Therapeutics News and Research

RSS

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

30 Jan 2012

Cell Therapeutics voluntarily withdraws Pixuvri NDA for NHL

Cell Therapeutics, Inc. announced today that it has voluntarily withdrawn its New Drug Application for Pixuvri (pixantrone) for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed two or more lines of prior therapy.

30 Jan 2012

Researchers develop new physical form of proteins to improve treatments for cancer

A new physical form of proteins developed by researchers at The University of Texas at Austin could drastically improve treatments for cancer and other diseases, as well as overcome some of the largest challenges in therapeutics: delivering drugs to patients safely, easily and more effectively.

30 Jan 2012

Researchers identify dual role of key player in human immune system

Northwestern University Feinberg School of Medicine researchers have identified a new and unusual role for a key player in the human immune system. A protein initially believed to regulate one routine function within the cell has proven vital for another critical step in the activation of the immune system.

30 Jan 2012

Susan Mallery finds breakthrough treatment for oral cancer

Dr. Susan Mallery, a professor in the College of Dentistry at The Ohio State University and Oral Pathology Consultant at the Ohio State University and James Cancer hospitals, has dedicated her nearly 30-year career to studying new strategies to preventing oral cancer.

30 Jan 2012

DNA sequencing for difficult diagnoses of mitochondrial diseases may hit clinics soon

Identifying complete DNA sequences could identify difficult-to-diagnose diseases in humans. This concept is being used for the first time in a clinic. MitoExome sequencing uses new technologies known as next-generation sequencing (NGS) to decode all of the genes associated with mitochondria. Mitochondria are a capsule shaped organelle present within the cell. It is the powerhouse of the cell and its genes are inherited completely from the mother.

29 Jan 2012

Scientists develop new vaccine to treat cancer at pre-clinical level

Scientists in Trinity College Dublin, Ireland, have developed a new vaccine to treat cancer at the pre-clinical level. The research team led by Professor Kingston Mills, Professor of Experimental Immunology at Trinity College Dublin discovered a new approach for treating the disease based on manipulating the immune response to malignant tumours.

27 Jan 2012

Amgen enters definitive merger agreement to acquire Micromet

Amgen and Micromet, Inc. today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash.

27 Jan 2012

Celgene signs definitive merger agreement to acquire Avila

Celgene Corporation and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced a definitive merger agreement under which Celgene Corporation will acquire Avila Therapeutics, Inc.

26 Jan 2012

BioTime obtains license from Wistar Institute for technology related to SP100 gene

BioTime, Inc. today announced that it has obtained an exclusive license from The Wistar Institute in Philadelphia, PA for technology related to a gene designated as SP100.

25 Jan 2012

Prosensa secures €23M in new equity financing

Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced today that it has raised €23 million in new equity financing.

25 Jan 2012

GUMC licenses worldwide rights of 'theranostic' to BioMetrx

Georgetown University Medical Center (GUMC) has licensed worldwide rights of a potential novel cancer therapy and diagnostic, or "theranostic," to BioMetrx, LLC. The agent was invented by two Georgetown researchers.

25 Jan 2012

Cytori's ADRCs safe and feasible for patients with AMI

Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction, as Research Correspondence in the Journal of the American College of Cardiology.

25 Jan 2012

Echo commences Symphony tCGM System trials in critical care patients

Echo Therapeutics, Inc., a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude SkinPrep System for transdermal drug delivery, today announced that it is initiating clinical studies of its Symphony tCGM System in critical care patients.

25 Jan 2012

Genoscience, BioLineRx to develop and commercialize BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience, a French company focused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C.

24 Jan 2012

Cholesterol receptor allows entry of HCV virus into human liver cells

A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus, the first step in hepatitis C infection, according to research at the University of Illinois at Chicago College of Medicine.

24 Jan 2012

Pernix obtains marketing rights to new gastroenterology product in the U.S.

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced it has entered into a license and supply agreement with a private company for a new FDA-approved prescription product to treat gastroenterology disease.

24 Jan 2012

ImmunoCellular initiates enrollment in ICT-107 Phase II trial for GBM in 23 centers

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

24 Jan 2012

Guided Therapeutics seeks CE Mark approval for LuViva Advanced Cervical Scan

Guided Therapeutics, Inc. today announced that it has submitted the application for CE Mark approval for LuViva Advanced Cervical Scan. The CE Mark is required to market LuViva in the 27 nations that comprise the European Union (EU).

23 Jan 2012

EntreMed announces $10 million in financing from strategic accredited investors

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has secured $10 million in financing with strategic accredited investors, including IDG-Accel China Growth Fund II L.P., Emerging Technology Partners, LLC, and Dr. Tak W. Mak, Director of The Campbell Family Institute for Cancer Research.

23 Jan 2012